Results 201 to 210 of about 1,442,988 (353)

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action [PDF]

, 2007
Zhengxing Qu, David M. Goldenberg, Thomas M. Cardillo, Victoria Shi, Hans J. Hansen, Chien‐Hsing Chang   +5 more
openalex   +1 more source

Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells

Nature Biomedical Engineering, 2021
Longchao Liu, Jiahui Chen, J. Bae, Huiyu Li, Zhichen Sun, Casey Moore, Eric J Hsu, Chuanhui Han, J. Qiao, yang-xin fu   +9 more
semanticscholar   +1 more source

Pyrotinib and Nab‐Paclitaxel in HER2‐Positive Breast Cancer (PANHER Trial): A Prospective, Single‐Arm, Phase II Trial

Cancer Science, EarlyView.
In this multicenter, single‐arm, open‐label phase II trial, patients with HER2‐positive breast cancer who had previously received chemotherapy with taxanes or anthracyclines were enrolled to receive pyrotinib combined with nab‐paclitaxel, and the results demonstrated promising efficacy with an acceptable safety profile.
Huan Li, Min Yan, Zhaohui Li, Xiujie Cui, Xuening Ji, Fengqi Fang, Yuyang Zhang, Yan Wang, Xiangyu Guo, Mingxi Jing, Zhichao Gao, Hui Cao, Fangyuan Dong, Jie Wu, Cui Jiang, Yangyang Duan, Xiaorui Li, Yujun Jiang, Lei Jiang, Ying E, Yufeng Jia, Liang Zhang, Pai Peng, Tao Sun   +23 more
wiley   +1 more source

Bispecific Antibodies for Lymphoid Malignancy Treatment. [PDF]

Cancers (Basel)
Bisio M, Legato L, Fasano F, Benevolo Savelli C, Boccomini C, Nicolosi M, Santambrogio E, Freilone R, Novo M, Botto B.   +9 more
europepmc   +1 more source

Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct [PDF]

, 2007
Scott A. Hammond, Ralf Lutterbuese, Shannon Roff, Petra Lutterbuese, Bernd Schlereth, Elizabeth Bruckheimer, Michael S. Kinch, Steve Coats, Patrick A. Baeuerle, Peter Kufer, Peter A. Kiener   +10 more
openalex   +1 more source

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Objective Melphalan flufenamide (melflufen) plus dexamethasone is fully approved in Europe for patients with relapsed/refractory multiple myeloma (RRMM) with ≥ 3 prior lines of therapy. We analyzed the efficacy and safety of melflufen in the real‐world setting.
Shahrier Hossain, Clifton Mo, Sarah Patches, Houry Leblebjian, Kathryn Goodrich, Eileen Regan, Kathleen O'Neill, Kim Noonan, Paul G. Richardson, Jacob Laubach   +9 more
wiley   +1 more source

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL. [PDF]

Cancers (Basel)
Kordic A, Phillips TJ, Weiss J.
europepmc   +1 more source

Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin [PDF]

, 2007
Dafne Müller, Anette Karle, Bettina Meißburger, Ines Höfig, Roland Stork, Roland E. Kontermann   +5 more
openalex   +1 more source

Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies

European Journal of Haematology, EarlyView.
ABSTRACT The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have demonstrated remarkable efficacy, achieving high response rates and minimal residual disease (MRD) negativity ...
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma. [PDF]

Cancers (Basel)
Jean-Louis G, Cherng HJ.
europepmc   +1 more source